Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Articles by Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Latest Updated Articles
- Study Summary: Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis
Published: August 13th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Photobiomodulation, Bio-Machines, and the Future of Dermatology
2
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
3
The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine
4
Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026
5
